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Abstract
Background/Aim: The changes in the cerebrospinal fluid (CSF) metabolome associated with the fatal neurodegenerative
disease amyotrophic lateral sclerosis (ALS) are poorly understood and earlier smaller studies have shown conflicting results.
The metabolomic methodology is suitable for screening large cohorts of samples. Global metabolomics can be used for
detecting changes of metabolite concentrations in samples of fluids such as CSF.
Methodology: Using gas chromatography coupled to mass spectrometry (GC/TOFMS) and multivariate statistical modeling,
we simultaneously studied the metabolome signature of ,120 small metabolites in the CSF of patients with ALS, stratified
according to hereditary disposition and clinical subtypes of ALS in relation to controls.
Principal Findings: The study is the first to report data validated over two sub-sets of ALS vs. control patients for a large set
of metabolites analyzed by GC/TOFMS. We find that patients with sporadic amyotrophic lateral sclerosis (SALS) have a
heterogeneous metabolite signature in the cerebrospinal fluid, in some patients being almost identical to controls.
However, familial amyotrophic lateral sclerosis (FALS) without superoxide dismutase-1 gene (SOD1) mutation is less
heterogeneous than SALS. The metabolome of the cerebrospinal fluid of 17 ALS patients with a SOD1 gene mutation was
found to form a separate homogeneous group. Analysis of metabolites revealed that glutamate and glutamine were
reduced, in particular in patients with a familial predisposition. There are significant differences in the metabolite profile and
composition among patients with FALS, SALS and patients carrying a mutation in the SOD1 gene suggesting that the
neurodegenerative process in different subtypes of ALS may be partially dissimilar.
Conclusions/Significance: Patients with a genetic predisposition to amyotrophic lateral sclerosis have a more distinct and
homogeneous signature than patients with a sporadic disease.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset heteroge-
neous syndrome with multiple clinical, genetic and histological
subtypes with ill-defined borders [1,2]. The clinical hallmarks of
the syndrome are focal onset of symptoms and signs of
degeneration of primarily upper and lower motor neurons,
eventually leading to progressive generalized paresis of bulbar,
limb, thoracic and abdominal skeletal muscles. Other brain
functions, including oculomotor and autonomic functions, are
relatively spared, though these may be involved in some patients.
Cognitive dysfunction occurs in 25–50%, and 5–15% of patients
develop dementia that is usually of frontotemporal type; semantic
dementia or progressive non-fluent aphasia. In epidemiological
studies in different populations, familial ALS (FALS) is reported by
1–18% of patients, and presently mutations in ten genes have been
found to cause ALS. The most commonly mutated gene in FALS
is the gene encoding the oxygen-radical scavenging enzyme
superoxide dismutase-1 (SOD1), mutations in which have been
found in 12–23% of patients with a diagnosis of FALS and in 1–
7% of patients carrying a diagnosis of sporadic ALS (SALS)[3].
The other genes found mutated in ALS have been found in 2% or
less of cases and include genes involved in axonal transportation,
angiogenesis and RNA processing without a common denomina-
tor except for the ALS phenotype. Genomic studies suggest the
existence of at least eleven additional loci for FALS, but the
genetic defects remain to be identified [3].
Post-mortem histological hallmarks of ALS are reduction in
number of spinal anterior horn motor neurons and the presence of
Bunina bodies and ubiquinated cytoplasmic inclusions in the
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immunoreactive to antibodies against the TAR DNA binding
protein (TDP-43) and p62. Interestingly, immunoreactivity to
TDP-43 appears to be rare or absent in patients with SOD1 gene
mutations suggesting that these may follow a different neurode-
generative pathway [4,5].
ALS is invariably fatal, the median survival time is 2.5 years
before the patient succumbs, usually to paralysis of the respiratory
muscles. Epidemiological and neurophysiological studies and
studies in transgenic rodent models with mutations in the SOD1
gene suggest that the actual pathogenic process begins much
earlier and not only involves neurons but also T-cell and glial cell
populations as well as endothelial cells involved in maintaining the
blood-brain barrier [6].
A number of studies of plasma, serum and/or cerebrospinal
fluid (CSF) have failed to identify the key components in the
neurodegenerative process in ALS. Series of transcriptomic and
proteomic studies have given diverging and frequently inconclu-
sive results with few validated early findings. Reduced levels of
cystatin C and increased levels of neurofilaments have been
proposed as CSF biomakers for ALS [7,8]. A recent proteomic
study found a relationship between the levels of Galectin-3 to be
indicative of the onset of ALS symptoms in mice and the result was
found transferrable to ALS [9]. Metabolomics should be seen as a
complementary technique to genomics, transcriptomics and
proteomics. In 2005, the first metabolomic study of ALS reported
reduced levels of a broad variety of metabolites in blood plasma
although the results were inconclusive [10]. Recently, Blasco et al.
[11] reported a proton nuclear magnetic resonance (
1H-NMR)
based metabolomic study of CSF from 50 ALS patients and 44
controls (non-neurological diseases). Acetone, pyruvate and
ascorbate were found significantly increased while acetate was
found decreased in ALS compared to controls, respectively. In this
interesting study, only a small part of the metabolome was studied.
The authors concluded that perturbations in energy metabolism
and ketone metabolism were associated with ALS. However, other
earlier studies of ascorbate metabolism have showed contradictory
results [12,13]. We here report a carefully designed study of the
human CSF metabolome in a larger group of patients with
different clinical and genetic subtypes of ALS. This study reports
data validated over two sub-sets of ALS vs. control patients for a
large set of metabolites analyzed by GC/TOFMS.
Methods
Sample collection, handling and storage
The study was performed in accordance with the Declaration of
Helsinki (WMA, 1964) and approved by the medical ethical
research board at the University of Umea ˚, Sweden. With written
informed consent CSF was collected from ALS patients divided
into two groups (set I, set II), each group consisting of 39 ALS
patients: Set I (19 males, 20 females; 30 SALS and 9 FALS; 8 with
bulbar onset, 31 with spinal onset; 6 with SOD1 gene mutations)
and Set II (20 males, 19 females; 25 SALS and 14 FALS; 9 with
bulbar onset, 30 with spinal onset; 12 with SOD1 gene mutations).
The ALS patients were diagnosed by the same neurologist
according to standard criteria [3]. Cases were classified as FALS
when two, or several members in the same family had been
diagnosed with ALS. The remaining cases were classified as SALS.
The selection process is summarized in Figure S1 and the
characteristics of each patient and their respective controls are
summarized in Table S1. For each patient, one or more control
individual(s) were carefully selected matched for age, gender and
the time the CSF sample had been in freezer storage. In set I, some
of the ALS patients were assigned to match more than one control
to account for the possibility that the matched control may have a
disease that could show differences in the metabolite pattern
towards ALS. Multiple ALS subjects were also matched to the
same control to account for the inverse, i.e that different ALS
subtypes may show a different metabolic response compared to the
same control. In set II, only one control was matched to each ALS
patient. The control patients either suffered from a neurological
condition or were healthy subjects. Details for each ALS-patient
and the corresponding control are summarized in Table S1. The
CSF was tapped as part of the initial clinical investigation before
treatment with riluzole was initiated. In a few patients, the spinal
tap was performed as part of a secondary investigation and these
patients were usually already medicating with riluzole (Table S1).
In all patients, a spinal tap was performed at the L:4-L:5 or L:5-
LS1 levels with the individual lying in a horizontal resting fetal
position (right side down). The spinal taps were performed non-
traumatically without visible or laboratory evidence (enumeration
in a Bu ¨rker Champer) for hemorrhage using a 20 G SpinocanH
cannula (patients in which even the smallest hemorrhage in the
CSF was detected were excluded from the study) as described [14].
The CSF used in the present study was among the first 4 ml
collected. Upon collection, the CSF was immediately frozen in
1 ml polypropylene tubes to 280uC as described [14]. None of the
individuals were fasting at the time of the tapping. The ALS
patients were stratified according to clinical subtype of ALS
(gender, bulbar or spinal onset, familial or sporadic disease) and
results of genetic analysis (SOD1 mutation/non-SOD1 mutation).
Genetic analysis
All patients were screened for DNA-mutations in the following
genes: SOD1, vesicle associated membrane protein B, TDP-43,
fused in sarcoma (FUS), progranulin, chromatin modifying protein
2B, optineurin, ataxin 2 and angiogenin using standard procedures
as described [15,16,17,18,19,20,21,22,23]. Only patients with a
SOD1 gene mutation or patients without a mutation in any of the
analyzed genes were included in this study.
Metabolomic analysis
CSF from the two groups (set I and set II) of ALS patients
(39+39) and their matching controls were analyzed using gas
chromatography - time of flight mass spectrometry (GC/TOFMS)
with 6 months in between. Division into the two sample sets (I and
II) was done to validate disease related findings in two separate
cohorts over time. Biological (samples from the same subject
extracted, derivatized and analyzed separatelt) and analytical (the
same sample being injected on the GC multiple times) replicates
were made in both sets to assess the stability of the method for
both control and ALS subjects. In order to obtain a reasonable
number of samples in each GC/MS run only a selection of the
samples were replicated. Samples from patients and controls were
analyzed in a randomized order in set I, and in a pair-wise
randomized order in set II where permutation was made to decide
which sample was first analyzed for each pair. The combination of
the two methods for validation was employed to minimize the risk
to get results based on spurious correlations from the data
collection.
Extraction of CSF, derivatization of extracted metabolites, GC/
TOFMS analysis, data pre-processing and metabolite identifica-
tion were carried as outlined in Figure S2 and described in
Methods S1 and [14]. The study was performed in accordance
with the standards proposed by the Chemical Analysis Working
Group and Metabolomics Standards Initiative for chemical
analysis and practices related to analysis of the metabolome [24].
Abnormal CSF Metabolomics by GC/TOFMS in ALS
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Multivariate statistical modeling was performed by means of
orthogonal partial least squares discriminant analysis (OPLS-DA)
[25]. OPLS was developed to deal with complex data consisting
of systematic variation from multiple origins (biological, analyt-
ical, etc.), such as metabolomic data, by splitting information in
one part correlated to a certain response (for example disease
status), and one part uncorrelated (i.e. orthogonal) to the
response. This provides OPLS with the advantage, compared
to other generalized inverse regression models, that it facilitates
model interpretation and visualizations of both types of
variations [26]. A special case of OPLS is when the response
is constructed as dummy variables holding information about the
sample class called discriminant analysis (DA). Variables
(metabolites) are extracted that discriminates between the sample
classes (the method is hence called OPLS-DA). For details
regarding OPLS-DA please see Methods S1 and Figures S3 and
S4 [25].
Validation of models was done using full cross validation (CV),
CV-analysis of variance [27] and in some cases prediction of
model independent samples. In detail, models were calculated in
set I and set II for the differences between i) ALS and control, ii)
FALS and control, iii) SALS and control, for set I and set II. For
specific sub-group comparisons of all ALS cases (FALS/SALS,
SOD1 mutation/non-SOD1 mutation) a third set (set III) was
constructed based on set I and set II. The same data pretreatment
was used for set I as for set II and for each ALS subject the
matched control was subtracted. For set III models were
calculated for the differences between i) FALS and SALS and ii)
ALS cases with and without SOD1 mutations. For models
revealing significant disease-related separations important metab-
olites were highlighted and subjected to further validation. All
variables were used for modeling of training set and predictions
(centered and scaled to unit variance). All multivariate statistical
modeling was carried out in SIMCA P+12.0 (Umetrics, Umea ˚,
Sweden). Model plots were created using Evince 2.3.1 (UmBio AB,
Umea ˚, Sweden).
The total sum of variables (artifacts, exogenous compounds and
internal standards excluded) was calculated for each subject. T-test
was used to calculate p-values for the differences between i) ALS
and control, ii) FALS and matched controls, iii) SALS and
matched controls, iv) FALS and SALS and v) matched controls for
FALS and matched controls for SALS of the total sum of variables.
For SOD1 mutations no test were performed due to the small
number of individuals.
Results
ALS versus controls
OPLS discriminant analysis (OPLS-DA) was used to screen the
data for alterations in metabolites related to disease classification
(control versus ALS). Modeling of the two datasets I and II
separately, revealed separation/overlap between subjects diag-
nosed with ALS compared to their matched controls. The
separation was more distinct in set I as compared to set II (Fig. 1)
and it was found that the separation was caused by a few samples
(mainly SALS cases) not following the common disease pattern
(Fig. 1 a and c). The common disease pattern was further
enhanced by subtracting the model score values for the matched
control subject from each corresponding ALS case to give all
control samples a common starting value of zero. ALS samples
systematically move in a common ALS direction in the
‘‘metabolic space’’. In set I, one FALS subject was misclassified
when compared to a control subject diagnosed with chronic
fatigue syndrome. The same FALS was correctly classified
compared to a healthy control (1 misclassified/39 in set I). In
set II seven SALS cases were misclassified (7 misclassified/39 in
set II). The pattern was hence generally more consistent for
samples classified as FALS as compared to cases classified as
SALS (Fig. 1 b and d). FALS was found to be a more
homogenous group in the obtained model scores (set I: standard
deviation (SD)=61.21; set II: SD=61.14) compared to SALS
(set I: SD=61.38; set II: SD=62.22).
Subdivision into familial and sporadic ALS cases
To address more specific changes of SALS and FALS
respectively in the CSF metabolome, the individual groups where
modeled together with the corresponding matched controls.
OPLS-DA models between FALS and the matched controls
revealed a significant separation between the FALS cases from the
matched control in both set I and set II (Fig. 2). However, for the
SALS cases significant separation from controls was only found in
set I. This was in accordance to what was seen when modeling
ALS against controls.
The FALS and SALS cases from both set I and II were then
included in the same model following subtraction of the matched
control values from the corresponding ALS subject (named set III).
Comparison of FALS and SALS cases revealed a significant
difference between the two ALS subtypes (Fig. 3 a). In addition,
when excluding two subjects classified as SALS but carrying a
SOD1 mutation an even stronger model for the separation was
obtained. Prediction of the two excluded SALS cases (SOD1
positive) into the model placed them closer to the group of FALS
cases as compared to SALS (Fig. 3 b).
Subdivision into ALS cases with and without SOD1
mutations
Seventeen of the samples were from patients with one of 6
different SOD1 gene mutations (please see Table S1 for details).
Comparison of the metabolome of these ALS patients to the SALS
and FALS patients without SOD1 mutations, revealed a
significant separation between the groups (Fig. 4 a). Furthermore,
a significant separation was found when comparing carriers of a
mutation in the SOD1 gene (FALS and SALS) to SALS cases
negative for SOD1 mutations (hence excluding all SOD1 negative
FALS cases). Prediction of SOD1 mutation negative FALS cases
into the model placed four out of six samples in the group of SALS
cases negative for SOD1 mutations while two samples ended up
on the border between the groups (Fig. 4 b).
For a summary of the statistics of all calculated OPLS-DA
models see Table 1.
Metabolite detection and identification
In total 120 peaks (e.g. potential metabolites) were detected
with GC/TOFMS of which forty metabolites were identified.
Eighty peaks were found to be potential metabolites but could
not be identified with high enough certainty using chemical
reference libraries. Around thirty of the eighty unidentified
compounds could still be assigned to compound class. The
overall alterations including metabolites highlighted as contrib-
uting to the significant separations in the models reported above
are summarized in Table S2. The total sum of variables was
found to be significantly different between the group of FALS
patients and the group of matched controls (p ,0.05 for both set
I and set II) as well as between FALS and SALS (p ,0.05 for
both set I and set II).
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The metabolome consists of highly covarying metabolites [28].
This is to date the largest study to cover a larger proportion of the
human CSF metabolome in patients with a neurodegenerative
disease compared to controls. Earlier metabolomic studies in ALS
have focused on a few metabolites like glutamic acid, aspartic acid,
homocysteine [29], creatinine, lactic acid/pyruvic acid, lipid
metabolism and not on metabolomic profiling as in the present
study. In the earlier reports, no consistent abnormality has been
found validated over several studies. Using
1H-NMR to study 17
metabolites in the CSF from 50 ALS patients, Blasco et al. recently
found significantly lower acetate concentrations, a trend for an
increase in acetone, and significant increases in the concentrations
of both pyruvate and ascorbate in ALS compared to 44 controls
[22]. Although
1H-NMR spectroscopy is a robust method for
analysis of many metabolites, GC/TOFMS has the advantage to
discover changes in metabolites present at lower concentrations
due to the increased sensitivity (for instance, to analyze metabolites
such as glutamic acid) hence NMR and mass spectrometry should
be regarded as complementary techniques. Glutamic acid was in
the present study found to be reduced in CSF from the ALS
Figure 1. OPLS-DA model results for all ALS versus controls. (A) OPLS-DA model score vector t[1]P vs. matched sample pairs showing
separation between controls and ALS (SALS and FALS) in set I. (B) Showing the separation between controls and ALS samples (SALS and FALS) after
subtraction of control score values from matched ALS case score value in set I. (C) OPLS-DA model score vector t[1]P vs. matched sample pairs
showing separation between controls and ALS samples (SALS and FALS) in set II. (D) The separation between control and ALS samples (SALS and
FALS) after subtraction of control score values from matched ALS score values in set II. Red circles, SALS; blue triangles, FALS; black circles, control.
doi:10.1371/journal.pone.0017947.g001
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and using different methodologies and usually only a small
number of patient samples, glutamic acid has been reported as
being elevated, normal or reduced in the CSF of ALS patients
[30,31,32]. The studies reporting an increase in CSF glutamic acid
content has by some been taken as support for the theory of
glutamic acid exitotoxicity as a cause of ALS [30]. We have
recently reported that glutamic acid in CSF is highly susceptible to
Figure 2. OPLS-DA model of FALS versus controls. OPLS-DA model score vector t[1]P vs. matched sample pairs showing separation between
control (black circles) and FALS samples (blue triangles) for set I (A) and for set II (B).
doi:10.1371/journal.pone.0017947.g002
Figure 3. OPLS-DA model of SALS versus FALS. (A) OPLS-DA model score vector t[1]P for the model between SALS samples and FALS samples
showing a clear difference between the sample groups. Two patients later found to carry SOD1 mutations (D90Amc and D90Amm) were initially
diagnosed as apparently SALS. (B) OPLS-DA model score vector t[1]P for the model between SALS samples and FALS samples when excluding the
two SALS patients carrying SOD1 mutations (D90Amc and D90Amm). Predictions of the two excluded samples (marked with stars) placed them into
the FALS group. Blue triangles, FALS; red circles, SALS.
doi:10.1371/journal.pone.0017947.g003
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(220uC versus 280uC) [14]. Higher values of glutamic acid are
found in CSF samples stored even for a short time at room
temperature or 220uC. In our experience, rigorous quick
handling of freshly drawn CSF, low storage temperature and the
careful matching of stored ALS and control samples are essential
for reliable assessment of glutamic acid and other metabolites in
the CSF.
In contrast to the interesting study by Blasco et al. [11], we find
that the content of ascorbic acid to be non-significantly different
between ALS and controls in both set I and set II (non-significant
increased in set I, non-significant decreased in set II).
Figure 4. OPLS-DA results for patients with SOD1 gene mutations. (A) OPLS-DA score vector t[1]P showing the difference between ALS
samples with (blue triangles) and without (red circles) mutation in the SOD1 gene. (B) Prediction of six FALS cases (some replicated) without SOD1
mutation (open blue triangles marked with stars) into an OPLS-DA model between samples with mutation in the SOD1 gene and SALS samples
without mutation in the SOD1 gene places the four FALS cases without mutation in the non-SOD1 group and two on the borderline between the
groups (samples predicted to have a positive value along tPS [1]).
doi:10.1371/journal.pone.0017947.g004
Table 1. OPLS-DA model diagnostics.
Model
number Model between Dataset
Number of model
components R2X (t1P) R2X R2Y Q2 CV-ANOVA
1 ALS-Controls Set I 1+1+0 0,050 0,162 0,567 0,311 8,52*10
-7
2 ALS-Controls Set II 1+1+0 0,044 0,306 0,340 -0,143 n.s.
3 FALS-Controls Set I 1+0+0 0,201 0,201 0,529 0,265 4,77*10
-2
4 FALS-Controls Set II 1+2+0 0,061 0,453 0,896 0,400 4,73*10
-2
5 SALS-Controls Set I 1+1+0 0,055 0,175 0,604 0,236 2,15*10
-3
6 SALS-Controls Set II 1+0+0 0,209 0,209 0,238 -0,136 n.s.
7 FALS-SALS Set I 1+0+0 0,148 0,148 0,396 0,263 7,70*10
-4
8 FALS-SALS Set II 1+1+0 0,146 0,345 0,730 0,411 1,13*10
-4
9 FALS-SALS Set III 1+1+0 0,064 0,220 0,475 0,219 2,65*10
-5
10 FALS-SALS (prediction
of mutation SALS)
Set III 1+3+0 0,036 0,332 0,732 0,316 4,91*10
-6
11 SOD1-nonSOD1 Set III 1+4+0 0,037 0,358 0,860 0,428 9,35*10
-9
12 SOD1-nonSOD1
(prediction of FALS)
Set III 1+1+0 0,070 0,223 0,542 0,325 8,76*10
-8
R2X (t1P): How much of the variation in X is directly related to Y; predictive variation in X. R2X: How much of the variation in X is explained by the model. R2Y: How
much of the variation in Y is explained by the model. Q2: How much of the variation in Y can be predicted by the model. CV-ANOVA: P-value for the separation between
sample groups based on cross validated model scores.
doi:10.1371/journal.pone.0017947.t001
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compound, creatine and creatine phosphate, are important for the
energy metabolism and are present at high levels in the CNS. The
major formation of creatinine in the body, however, takes place in
the skeletal muscles. CSF creatinine levels reflect both local
production of the compound and plasma creatinine levels [33].
This suggests that amyotrophy is the most likely explanation to the
lower CSF creatinine levels in ALS.
The patients with 6 SOD1 gene mutations with different clinical
and genetic subtypes (dominant versus recessive inheritance) of
ALS and very variable survival times had a rather uniform
metabolomic signature suggesting a common neurodegenerative
pathway for patients with this type of ALS, but no single abnormal
metabolite could be identified. The 6 FALS patients without a
SOD1 gene mutation were less homogeneous than the mutant
SOD1 group, and notably did not overlap with this group, possibly
because of alternative degenerative pathways. Unfortunately, no
CSF samples fulfilling the stringent sampling criteria used in this
study were available from patients with mutations in other
identified ALS genes. The patients with a SALS diagnosis without
a SOD1 gene mutation appeared as a more heterogeneous group
possibly because of multiple disease pathways. Some overlap
between SALS with the control group was found. The 8 SALS
cases that were most "control-like’’ did not share any common
other features, including co-existing or previous other diseases or
medication. Three of these SALS cases underwent post-mortem
examination confirming the ALS diagnosis.
The results indicate larger heterogeneity in metabolite patterns
among SALS cases compared to FALS, which were found to be
more defined as a group. One may speculate whether the results of
the study point towards either ALS as a group of diseases or one
disease showing diverse metabolic fluctuations due to various
combinations of symptoms related to the same disease or
alterations due to different rates of progression of the disease.
The variability may be one of the reasons for the relatively poor
model diagnostics when comparing ALS to controls and SALS to
controls. Other reasons may be the large diversity within the
control group consisting of patients of various neurological diseases
and errors of diagnosis (false positives or false negatives). Another
possibility is that the pathology in ALS is to only a limited extent
reflected in the sub-fraction of the CSF-metabolome captured in
the study.
However, some general systematic patterns possibly related to
disease were found. An overall trend was decreased levels of many
CSF metabolites in ALS. This is in accordance with the interesting
recent study of the plasma metabolome in ALS versus controls
[10]. Further analyses of the still non-covered part of the
metabolome and prospective studies are needed to draw general
mechanistic conclusions regarding disease related changes.
Limitations of the study
Riluzole is the only drug that has been shown to slow the course
of ALS in class I studies, by some attributed to its anti-
glutamatergic properties but the mechanism is unknown [34].
While most of the patients included in this study were without any
medication at the time of CSF collection, a few had been on
riluzole for weeks or months when the spinal tap was performed as
part of a second opinion evaluation (Table S1). Riluzole was not
detected in the CSF by GC/TOFMS, although there is a
possibility that metabolites of the drug may be present as non-
identified metabolites, as could effects of the drug on the
endogenous metabolome be present as a factor in the treated
patients. However, the design of the study including both riluzole-
treated and untreated ALS cases diminishes the risk that the
detected disease related model separations should be caused by
direct or indirect riluzole-induced metabolic alterations.
The present metabolomics study is based on GC/TOFMS
analysis. This type of analysis has its limitation as it can only cover
approximately 10–15% of the metabolome, and then mainly
primary metabolites such as amino acids, fatty acids, other organic
acids, mono- and disaccharides. Today no single analytical
platform can analyze the whole metabolome. Instead a combina-
tion of GC/MS, LC/MS and NMR are required to cover an
extended proportion of the entire metabolome. Such a global
metabolomics study will be of the greatest interest but will demand
extensive laboratory resources and large volumes of CSF. It must
also be emphasized that many metabolites are still unidentified,
and therefore identification of metabolites in biological fluids such
as CSF will be of major importance for the future.
One advantage of using GC/TOFMS is that many compounds
can comparatively easily be identified, yet still only 30% of the
detected metabolites could be identified in this study (Table S2).
Obviously we are only at the beginning of tapping the wealth of
information contained in the metabolome in diseases.
Supporting Information
Figure S1 Algorithm for sample selection. Samples from
ALS subjects were ordered according to age and storage time in -
80uC freezer for males and females separately and two subsets
were selected and merged. Controls with various neurological
conditions and healthy subjects were matched according to sex,
age and storage time.
(TIFF)
Figure S2 Derivatization algorithm. The selected CSF
samples were extracted and derivatized according to the scheme
above prior to GC-TOFMS analysis.
(TIFF)
Figure S3 OPLS score vector t1[p] vs. matched sample
pairs. The figure present the separation between controls (open
squares) and matched ALS subjects (black squares) for group A
(left) and group B (right) based on an OPLS model against GC-
TOFMS run order showing nonsystematic patterns related to
disease.
(TIFF)
Figure S4 Algorithm for Data processing. Settings of
HMCR were optimized according to a full factorial design. Max
peak shift setting was kept constant at 45 scans while, filter length,
noise limit and retention time precision were adjusted according to
the paradigm in the figure. Nine datasets were evaluated for
number of resolved components, number of bad spectra (estimated
by median intensity of m/z values ? 0), number of split peaks of
internal standards, match according to library search of internal
standards and a selection of endogenous metabolites.
(TIFF)
Table S1 Characteristics of Patients and Controls in
Dataset I and Dataset II Abbreviations used: FTD, Fronto-
temporal dementia; NPH, Normal pressure hydrocephalus; PBP,
Progressive Bulbar Palsy; SBMA, Spino-bulbar muscular atrophy;
FALS, familial ALS; SALS, sporadic ALS; wt, wild-type SOD1
genotype; D90A/D90A, homozygosity for the D90A SOD1 allele
(mm); ALSFRS, ALS Functioning Rating Scale (40 is the score for
a healthy individual).
(XLS)
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set I and II contributing to differences in one or several
comparisons. Contribution in models of ALS-Controls, FALS-
Controls, FALS-SALS and mSOD1-wtSOD1 are shown. Abbre-
viations: Loadings (p1)*; Contribution (w*1)**; Exogenous***;
2/+ = decreased or increased in ALS, FALS or patients with a
SOD1 gene mutations; 0 = no change found; nf = not found by
analysis; blank = not found after cutoff 2/3.
(XLS)
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(DOC)
Acknowledgments
We are indebted to the patients for their participation in this project.
Author Contributions
Conceived and designed the experiments: AW TM HA PMA. Performed
the experiments: AW HA PMA. Analyzed the data: AW TM SLM HA
PMA. Contributed reagents/materials/analysis tools: TM HA PMA.
Wrote the paper: AW TM SLM HA PMA.
References
1. Haverkamp LJ, Appel V, Appel SH (1995) Natural-History of Amyotrophic-
Lateral-Sclerosis in a Database Population - Validation of a Scoring System and
a Model for Survival Prediction. Brain 118: 707–719.
2. Li TM, Alberman E, Swash M (1988) Comparison of Sporadic and Familial
Disease Amongst 580 Cases of Motor Neuron Disease. J Neurol Neurosurg
Psychiatry 51: 778–784.
3. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, et al. (2005)
EFNS task force on management of amyotrophic lateral sclerosis: guidelines for
diagnosing and clinical care of patients and relatives. Eur J Neurol 12: 921–938.
4. Aggarwal A, Nicholson G (2002) Detection of preclinical motor neurone loss in
SOD1 mutation carriers using motor unit number estimation. JNeurol
Neurosurg Psychiatry 73: 199–201.
5. Maekawa S, Leigh NP, King A, Jones E, Steele JC, et al. (2009) TDP-43 is
consistently co-localized with ubiquitinated inclusions in sporadic and Guam
amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with
and without SOD1 mutations. Neuropathology 29: 672–683.
6. Zhong ZH, Deane R, Ali Z, Parisi M, Shapovalov Y, et al. (2008) ALS-causing
SOD1 mutants generate vascular changes prior to motor neuron degeneration.
Nat Neurosci 11: 420–422.
7. Wilson ME, Boumaza I, Lacomis D, Bowse R (2010) Cystatin C: A Candidate
Biomarker for Amyotrophic Lateral Sclerosis. PLoS ONE 5: 15133.
8. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM (2007) CSF
Neurofilament light levels in amyotrophic lateral sclerosis: Impact of SOD1
genotype. Eur J Neurol 14: 1329–1333.
9. Zhou JY, Afjehi-Sadat L, Asress S, Duong DM, Cudkowicz M, et al. (2010)
Galectin-3 Is a Candidate Biomarker for Amyotrophic Lateral Sclerosis:
Discovery by a Proteomics Approach. J Proteome Res 9: 5133–5141.
10. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, et al. (2005)
Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1:
101–108.
11. Blasco H, Corcia P, Moreau C, Veau S, Fournier C, et al. (2010) H-1-NMR-
Based Metabolomic Profiling of CSF in Early Amyotrophic Lateral Sclerosis.
Plos One 5: e13223.
12. Ihara Y, Nobukuni K, Takata H, Hayabara T (2005) Oxidative stress and metal
content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients
with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res 27:
105–108.
13. Paraskevas GP, Kapaki E, Libitaki G, Zournas C, Segditsa I, et al. (1997)
Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer’s
disease. Acta Neurol Scand 96: 88–90.
14. Wuolikainen A, Hedenstro ¨m M, Moritz T, Marklund SL, Antti H, et al. (2009)
Optimization of procedures for collecting and storing of CSF for studying the
metabolome in ALS. Amyotrophic Lateral Sclerosis 10: 229–236.
15. Felbecker A, Camu W, Valdmanis PN, Sperfeld AD, Waibel S, et al. Four
familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1
mutations pathogenic? J Neurol Neurosurg Psychiatry 81: 572–577.
16. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, et al. (2006) Loss-of-
function ANG mutations segregate with familial and ’sporadic’ amyotrophic
lateral sclerosis. Nat Genet 38: 411–413.
17. Gros-Louis F, Andersen PM, Dupre N, Urushitani M, Dion P, et al. (2009)
Chromograinin B variats as a risk factor and modifier of disease onset for
amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 106: 21777–21782.
18. Sreedharan J, Blair IP, Tripathi VB, Hu X, Chance C, et al. (2008) TDP-43
mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319:
1668–1672.
19. Kwiatkowski TJ, Jr., Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR,
et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial
amyotrophic lateral sclerosis. Science 323: 1205–1208.
20. Parkinson N, Ince PG, Smith MO, Highley R, Skibinski G, et al. (2006) ALS
phenotypes with mutations in CHMP2B (Charged Multivesicular Body Protein
2B). Neurology 67: 1074–1077.
21. Schymick JC, Yang Y; Andersen PM, Vonsattel JP, Greenway M, et al. (2007)
Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral
sclerosis-frontotemporal dementia phenotypes. J Neurol Neurosurg Psychiatry
78: 754–756.
22. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, et al. (2010) Mutations of
optineurin in amyotrophic lateral sclerosis. Nature 465: 223–226.
23. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, et al. (2010)
Ataxin-2 intermediate length polyglutamine expansions are associated with
increased risk for ALS. Nature 466: 1069–1075.
24. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, et al. (2007) Proposed
minimum reporting standards forchemical analysis. Metabolomics 3: 211–221.
25. Bylesjo M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, et al. (2006)
OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA
classification. J Chemometrics 20: 341–351.
26. Trygg J, Wold S (2002) Orthogonal projections to latent structures (O-PLS).
J Chemometrics 16: 119–218.
27. Eriksson L, Trygg J, Wold S (2008) CV-ANOVA for significance testing of PLS
and OPLSH models. J Chemometrics 22: 594–600.
28. Brouns R, Van Hemelrijck A, Drinkenburg WH, Van Dam D, De Surgeloose D,
et al. (2010) Excitatory amino acids and monoaminergic neurotransmitters in
cerebrospinal fluid of acute ischemic stroke patients. Neurochem Int 56:
865–870.
29. Zoccolella S, Simone IL, Lamberti P, Specchio LM, Samarelli V, et al. (2008)
Elevated plasma homocysteine levels in patients with amyotrophic lateral
sclerosis. Neurology 70: 222–225.
30. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, et al. (1990)
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis.
Ann Neurol 28: 18–25.
31. Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, et al.
(2002) Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a
reappraisal using a new HPLC method with coulometric detection in a large
cohort of patients. J Neurol Sci 193: 73–78.
32. Perry TL, Krieger C, Hansen S, Eisen A (1990) Amyotrophic-Lateral-Sclerosis -
Amino-Acid Levels in Plasma and Cerebrospinal-Fluid. Ann Neurol 28: 12–17.
33. Tachikawa M, Kasai Y, Takahashi M, Fujinawa J, Kitaichi K, et al. (2008) The
blood-cerebrospinal fluid barrier is a major pathway of cerebral creatinine
clearance: involvement of transporter-mediated process. J Neurochem 107:
432–442.
34. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-
ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347:
1425–1431.
Abnormal CSF Metabolomics by GC/TOFMS in ALS
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e17947